These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 32624882)

  • 61. Controllable synthesis of versatile mesoporous organosilica nanoparticles as precision cancer theranostics.
    Cheng Y; Jiao X; Fan W; Yang Z; Wen Y; Chen X
    Biomaterials; 2020 Oct; 256():120191. PubMed ID: 32593907
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Mesoporous silica nanoparticles in drug delivery and biomedical applications.
    Wang Y; Zhao Q; Han N; Bai L; Li J; Liu J; Che E; Hu L; Zhang Q; Jiang T; Wang S
    Nanomedicine; 2015 Feb; 11(2):313-27. PubMed ID: 25461284
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Mesoporous Silica Nanomaterials: Versatile Nanocarriers for Cancer Theranostics and Drug and Gene Delivery.
    Kesse S; Boakye-Yiadom KO; Ochete BO; Opoku-Damoah Y; Akhtar F; Filli MS; Asim Farooq M; Aquib M; Maviah Mily BJ; Murtaza G; Wang B
    Pharmaceutics; 2019 Feb; 11(2):. PubMed ID: 30781850
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Nanocarriers for Biomedicine: From Lipid Formulations to Inorganic and Hybrid Nanoparticles.
    Kashapov R; Ibragimova A; Pavlov R; Gabdrakhmanov D; Kashapova N; Burilova E; Zakharova L; Sinyashin O
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209023
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Emerging and Innovative Theranostic Approaches for Mesoporous Silica Nanoparticles in Hepatocellular Carcinoma: Current Status and Advances.
    Tao Y; Wang J; Xu X
    Front Bioeng Biotechnol; 2020; 8():184. PubMed ID: 32211399
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Superior doxorubicin cellular delivery effect established by optically active mesoporous silica nanoparticles.
    Wang L; Yu D; Li D; Li J
    Drug Deliv Transl Res; 2024 Nov; 14(11):3163-3172. PubMed ID: 38381319
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Shape matters when engineering mesoporous silica-based nanomedicines.
    Hao N; Li L; Tang F
    Biomater Sci; 2016 Apr; 4(4):575-91. PubMed ID: 26818852
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Multi-functional silica-based mesoporous materials for simultaneous delivery of biologically active ions and therapeutic biomolecules.
    Zhu H; Zheng K; Boccaccini AR
    Acta Biomater; 2021 Jul; 129():1-17. PubMed ID: 34010692
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Mesoporous silica nanoparticles for therapeutic/diagnostic applications.
    Jafari S; Derakhshankhah H; Alaei L; Fattahi A; Varnamkhasti BS; Saboury AA
    Biomed Pharmacother; 2019 Jan; 109():1100-1111. PubMed ID: 30551360
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Hierarchical mesoporous silica nanoparticles for tailorable drug release.
    Wu W; Ye C; Xiao H; Sun X; Qu W; Li X; Chen M; Li J
    Int J Pharm; 2016 Sep; 511(1):65-72. PubMed ID: 27374197
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Radiolabeling Silica-Based Nanoparticles via Coordination Chemistry: Basic Principles, Strategies, and Applications.
    Ni D; Jiang D; Ehlerding EB; Huang P; Cai W
    Acc Chem Res; 2018 Mar; 51(3):778-788. PubMed ID: 29489335
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Overview of stimuli-responsive mesoporous organosilica nanocarriers for drug delivery.
    Guimarães RS; Rodrigues CF; Moreira AF; Correia IJ
    Pharmacol Res; 2020 May; 155():104742. PubMed ID: 32151682
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Functionalization of mesoporous silica nanoparticles for targeting, biocompatibility, combined cancer therapies and theragnosis.
    Kuthati Y; Sung PJ; Weng CF; Mou CY; Lee CH
    J Nanosci Nanotechnol; 2013 Apr; 13(4):2399-430. PubMed ID: 23763117
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Advances in Multicompartment Mesoporous Silica Micro/Nanoparticles for Theranostic Applications.
    Liu J; Liu T; Pan J; Liu S; Lu GQM
    Annu Rev Chem Biomol Eng; 2018 Jun; 9():389-411. PubMed ID: 29618224
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Aptamer-modified chitosan-capped mesoporous silica nanoparticles for co-delivery of cytarabine and daunorubicin in leukemia.
    Heydari SR; Ghahremani MH; Atyabi F; Bafkary R; Jaafari MR; Dinarvand R
    Int J Pharm; 2023 Nov; 646():123495. PubMed ID: 37806507
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Positioning metal-organic framework nanoparticles within the context of drug delivery - A comparison with mesoporous silica nanoparticles and dendrimers.
    Wuttke S; Lismont M; Escudero A; Rungtaweevoranit B; Parak WJ
    Biomaterials; 2017 Apr; 123():172-183. PubMed ID: 28182958
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Egg-yolk core-shell mesoporous silica nanoparticles for high doxorubicin loading and delivery to prostate cancer cells.
    Tiburcius S; Krishnan K; Jose L; Patel V; Ghosh A; Sathish CI; Weidenhofer J; Yang JH; Verrills NM; Karakoti A; Vinu A
    Nanoscale; 2022 May; 14(18):6830-6845. PubMed ID: 35441642
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Multifunctional mesoporous silica nanoparticles for biomedical applications.
    Xu B; Li S; Shi R; Liu H
    Signal Transduct Target Ther; 2023 Nov; 8(1):435. PubMed ID: 37996406
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Mesoporous silica nanoparticles for intracellular controlled drug delivery.
    Vivero-Escoto JL; Slowing II; Trewyn BG; Lin VS
    Small; 2010 Sep; 6(18):1952-67. PubMed ID: 20690133
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Cytostatic and Cytotoxic Effects of Hollow-Shell Mesoporous Silica Nanoparticles Containing Magnetic Iron Oxide.
    Pérez-Garnes M; Morales V; Sanz R; García-Muñoz RA
    Nanomaterials (Basel); 2021 Sep; 11(9):. PubMed ID: 34578771
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.